Kunming M. Qi

No. 99 West Huaihai Road
Xuzhou, 221002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.

Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.

Journal: BMC medicine

Published: February 07, 2026

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Journal: Blood

Published: February 03, 2026

Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia.

Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia.

Journal: Haematologica

Published: January 03, 2026

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

Journal: Frontiers in oncology

Published: December 10, 2025

The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations

The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 14, 2025

Effect of cytoreductive chemotherapy on the incidence of differentiation syndrome in patients with newly diagnosed acute promyelocytic leukemia.

Effect of cytoreductive chemotherapy on the incidence of differentiation syndrome in patients with newly diagnosed acute promyelocytic leukemia.

Journal: Chinese medical journal

Published: July 26, 2025

Nutritional status indices on the prognosis of patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.

Nutritional status indices on the prognosis of patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.

Journal: Frontiers in nutrition

Published: June 26, 2025

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.

Journal: Frontiers in immunology

Published: January 24, 2025

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: November 30, 2024

Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.

Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.

Journal: International urology and nephrology

Published: November 20, 2024

Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.

Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: November 20, 2024

The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy

The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy

Journal: Zhonghua yi xue za zhi

Published: August 21, 2024

Showing 1-12 of 77

Last Updated: 09/26/2026